First real-life data on COVID-19 vaccine effectiveness against hospitalisation and severe disease from the eastern part of the WHO European Region.
作者信息
Begovac Josip
机构信息
University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia.
出版信息
Lancet Reg Health Eur. 2024 Nov 5;47:101130. doi: 10.1016/j.lanepe.2024.101130. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
First real-life data on COVID-19 vaccine effectiveness against hospitalisation and severe disease from the eastern part of the WHO European Region.来自世界卫生组织欧洲区域东部的关于新冠病毒疫苗对住院治疗和重症疾病有效性的首批实际数据。
Lancet Reg Health Eur. 2024 Nov 5;47:101130. doi: 10.1016/j.lanepe.2024.101130. eCollection 2024 Dec.
2
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.AZD1222 初级系列疫苗接种对未接种加强针个体预防 COVID-19 住院的作用：欧洲 COVIDRIVE 研究的首个疫苗有效性结果及元回归分析
Lancet Reg Health Eur. 2023 Jul 1;31:100675. doi: 10.1016/j.lanepe.2023.100675. eCollection 2023 Aug.
3
Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.评估 SARS-CoV-2 感染严重形式的真实世界疫苗有效性：来自瑞士常规监测数据的观察性研究。
Swiss Med Wkly. 2022 Apr 19;152:w30163. doi: 10.4414/smw.2022.w30163. eCollection 2022 Apr 11.
4
COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study.新冠病毒疾病（COVID-19）疫苗对服用免疫抑制药物患者感染奥密克戎（B.1.1.529）变异株及住院治疗的有效性：一项回顾性队列研究
Lancet Rheumatol. 2022 Nov;4(11):e775-e784. doi: 10.1016/S2665-9913(22)00216-8. Epub 2022 Aug 16.
5
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.监测≥65 岁人群中电子健康记录的 COVID-19 疫苗对 COVID-19 住院和死亡的有效性：6 个欧洲国家，2021 年 10 月至 2022 年 11 月。
Influenza Other Respir Viruses. 2023 Nov;17(11):e13195. doi: 10.1111/irv.13195.
6
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民和工作人员中针对 SARS-CoV-2 感染、住院和死亡的疫苗有效性持续时间（VIVALDI）：一项前瞻性队列研究。
Lancet Healthy Longev. 2022 Jul;3(7):e470-e480. doi: 10.1016/S2666-7568(22)00147-7. Epub 2022 Jul 4.
7
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后，mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果：一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
8
A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province.一项关于BBIBP-CorV疫苗在斯里兰卡一个农村省份有效性的真实世界研究。
Heliyon. 2024 Sep 14;10(18):e37662. doi: 10.1016/j.heliyon.2024.e37662. eCollection 2024 Sep 30.
9
Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England.赛诺菲/葛兰素史克（维德Prevtyn Beta）和辉瑞-生物科技（原始/奥密克戎BA.4-5二价疫苗Comirnaty）二价疫苗在英格兰预防住院的有效性。
EClinicalMedicine. 2024 Apr 10;71:102587. doi: 10.1016/j.eclinm.2024.102587. eCollection 2024 May.
10
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.在英格兰，祖代单价疫苗的保护持续时间和二价 BA.1 加强针对 COVID-19 住院的有效性：一项病例对照研究。
Lancet Infect Dis. 2023 Nov;23(11):1235-1243. doi: 10.1016/S1473-3099(23)00365-1. Epub 2023 Jul 12.
引用本文的文献
1
COVID-19 Hospitalizations, Vaccine Uptake, Vaccination Guidelines, and Vaccine Availability in Six Middle-Income Countries and Areas in Europe, May 2022-April 2024.2022年5月至2024年4月欧洲六个中等收入国家和地区的新冠病毒肺炎住院情况、疫苗接种率、疫苗接种指南及疫苗可及性
Influenza Other Respir Viruses. 2025 Jun;19(6):e70126. doi: 10.1111/irv.70126.
2
Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines.葡萄牙医护人员在新冠疫情期间的纵向免疫学分析揭示了对疫苗体液免疫反应的差异。
Vaccines (Basel). 2024 Nov 30;12(12):1358. doi: 10.3390/vaccines12121358.
本文引用的文献
1
COVID-19 Disease Incidence and Severity in Persons Previously Infected and Unvaccinated vs Previously Uninfected and Vaccinated.既往感染且未接种疫苗者与既往未感染且接种疫苗者的新冠病毒疾病发病率和严重程度
J Infect Dis. 2025 Feb 4;231(1):115-120. doi: 10.1093/infdis/jiae484.
2
COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥18 Years - COVID-NET, 12 States, October 2023-April 2024.美国≥18 岁成年人中与 COVID-19 相关的住院治疗情况-COVID-NET，12 个州，2023 年 10 月至 2024 年 4 月。
MMWR Morb Mortal Wkly Rep. 2024 Oct 3;73(39):869-875. doi: 10.15585/mmwr.mm7339a2.
3
What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?是什么导致了东欧、南欧和西欧在 COVID-19 疫苗接种犹豫方面的差异？
Vaccine. 2023 May 11;41(20):3178-3188. doi: 10.1016/j.vaccine.2023.03.030. Epub 2023 Apr 4.
4
T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白中的T细胞表位在奥密克戎变体中基本保守。
Cell Mol Immunol. 2022 Mar;19(3):447-448. doi: 10.1038/s41423-022-00838-5. Epub 2022 Jan 18.
5
National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region.中东北欧地区艾滋病毒感染者的 COVID-19 疫苗接种国家战略。
HIV Med. 2022 May;23(5):546-552. doi: 10.1111/hiv.13194. Epub 2021 Oct 26.
Zotero 插件